Cite
HARVARD Citation
Burmester, G. et al. (2017). A randomised phase IIb study of mavrilimumab, a novel GM–CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis. Annals of the rheumatic diseases. 76 (6), pp. 1020-1030. [Online].